title: From the analyst's couch: TLR-targeted therapeutics.
authors.affiliation: J.P. Morgan, 50 Rowes Wharf, Boston, Massachusetts 02110, USA. eric.s.hoffman@jpmorgan.com
authors.forename: Eric S
authors.initials: ES
authors.lastname: Hoffman
authors.forename: Richard E T
authors.initials: RE
authors.lastname: Smith
authors.forename: Ronald C
authors.initials: RC
authors.lastname: Renaud
mesh_terms: D000276:Adjuvants, Immunologic / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D000634:Aminoquinolines / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D007113:Immunity, Innate / Q000187:drug effects* / Q000276:immunology; D040541:Marketing; D051193:Toll-Like Receptors / Q000276:immunology / Q000378:metabolism*
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D051193:Toll-Like Receptors; D000077271:Imiquimod